Coherus Oncology
CHRS
205 hedge funds and large institutions have $1.17B invested in Coherus Oncology in 2021 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 77 increasing their positions, 66 reducing their positions, and 25 closing their positions.
40% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 25
17% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 66
5% more funds holding
Funds holding: 196 → 205 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10.17% less ownership
Funds ownership: 120.54% → 110.37% (-10%)
22% less capital invested
Capital invested by funds: $1.51B → $1.17B (-$335M)
49% less call options, than puts
Call options by funds: $787K | Put options by funds: $1.54M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Swedbank
Stockholm,
Sweden
|
+$14.4M |
| 2 |
BlackRock
New York
|
+$11.6M |
| 3 |
SI
Scout Investments
Kansas City,
Missouri
|
+$9.35M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$8.74M |
| 5 |
Millennium Management
New York
|
+$6.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$38.2M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$34.7M |
| 3 |
VNIM
Vaughan Nelson Investment Management
Houston,
Texas
|
-$28.4M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$20.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$16M |
CHRS Hedge Fund Activity: Q1 2021 in Review
205 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2021, worth a combined $1.17B — down 22% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CHRS positions and 25 closed out — a net gain of 10 holders — while 77 added to existing stakes and 66 trimmed.
The largest buyer was Swedbank, opening a new position worth an estimated $14.4M. The largest seller was Camber Capital Management, exiting entirely with an estimated $38.2M sold.
- 205 institutional investors held Coherus Oncology (CHRS) as of Q1 2021, up from 196 in Q4 2020.
- Funds reported $1.17B of Coherus Oncology stock for Q1 2021, down 22% quarter-over-quarter.
- 35 funds opened new Coherus Oncology positions in Q1 2021 and 25 closed out, a net change of +10 holders.
- The largest Coherus Oncology buyer in Q1 2021 was Swedbank, an estimated $14.4M added.
- The largest Coherus Oncology seller in Q1 2021 was Camber Capital Management, an estimated $38.2M sold.
Based on aggregated 13F filings for Q1 2021.